Literature DB >> 2242580

Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood.

R W Yatscoff1, K R Copeland, C J Faraci.   

Abstract

We report here the evaluation of the Abbott TDx assay with a monoclonal antibody for selectively quantifying cyclosporine (CsA) in whole blood. Over the clinically relevant concentration ranges, results with this assay demonstrated within- and between-run CVs of less than 2.5% and 5%, respectively; sensitivity of 25 micrograms/L; good analytical recovery (100.3%); and linearity with whole-blood specimens. The percentage cross-reactivity of the major CsA metabolites varied from 15.3% for AM9 (M-1), 8.2% for AM1 (M-17), and 3.7% for AM4N (M-21), to less than 3% for the other metabolites tested. Results with the TDx assay (y) correlated well with those by the Sandimmune selective RIA (x; Sandoz) with blood specimens from 44 renal-transplant recipients (n = 44, x= 187.3, y = 198.9, y = 5.49 + 1.03x, r = 0.987). The TDx values were on average 24% higher than those by HPLC (x') with the same patients' specimens (n = 44, x' = 159.9, y = 198.9, y = 15.9 + 1.14x', r = 0.967). We conclude that the Abbott TDx monoclonal antibody assay provides a rapid, precise, and accurate means for quantifying CsA in whole blood.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242580

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT 2000 cyclosporine specific assay with the COBAS MIRA-plus analyzer.

Authors:  S Kimura; S Iyama; Y Yamaguchi; Y Kanakura
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

5.  Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.

Authors:  Pierre Wallemacq; Gregory T Maine; Keith Berg; Thomas Rosiere; Pierre Marquet; Giuseppe Aimo; Giulio Mengozzi; Julianna Young; Kurt Wonigeit; Robert Kretschmer; Bendicht Wermuth; Rainer W Schmid
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

6.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

Review 7.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 9.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

10.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

Authors:  T D Batiuk; F Pazderka; J Enns; L DeCastro; P F Halloran
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.